Here, we demonstrated that Mcl-1 levels appeared to increase in paclitaxel-resistant lung cancer cells and in the tumor nodules of mice who completed the paclitaxel treatment cycles (Fig. 5c, d). Here, MCL1 is linked to lung carcinoma.